$ADIL
ADIAL PHARMACEUTICALS, INC. Stock $adil

$adil Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000121390024043023 Filed on May 14, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.275M	$1.391M	$1.519M
YoY Change	21.69%	-38.03%	-27.75%
% of Gross Profit
Research & Development	$1.013M	$454.3K	$264.4K
YoY Change	135.53%	-32.84%	-76.74%
% of Gross Profit
Depreciation & Amortization	$140.00	$140.00	$560.00
YoY Change	-108.48%	-93.24%	-73.08%
% of Gross Profit
Operating Expenses	$2.287M	$1.845M	$1.784M
YoY Change	54.82%	-36.83%	-44.94%
Operating Profit	-$2.287M	-$1.845M
YoY Change	54.82%	-36.83%
Interest Expense	-$171.1K	-$167.1K	-$182.7K
YoY Change	-980.44%	-678.3%	-481.97%
% of Operating Profit
Other Income/Expense, Net	-$171.1K	-$4.632M	$62.06K
YoY Change	426.77%	-31200.85%	-80.9%
Pretax Income	-$2.458M	-$6.477M	-$1.904M
YoY Change	62.82%	122.88%	-33.58%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$2.458M	-$6.477M	-$1.920M
YoY Change	-325.99%	122.88%	-33.01%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.59	-$2.19
Diluted Earnings Per Share	-$0.59	-$2.19	-$1.34
COMMON SHARES
Basic Shares Outstanding	4.233M shares	4.055M shares	1.218M shares
Diluted Shares Outstanding	4.183M shares	2.954M shares

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.288M	$5.025M	$2.827M
YoY Change	169.91%	117.29%	-29.35%
Cash & Equivalents	$3.288M	$5.025M	$2.827M
Short-Term Investments
Other Short-Term Assets	$535.4K	$311.4K	$371.6K
YoY Change	485.91%	-52.25%	-52.25%
Inventory
Prepaid Expenses	$346.8K	$36.00K
Receivables
Other Receivables
Total Short-Term Assets	$3.823M	$5.336M	$3.199M
YoY Change	86.79%	80.0%	-33.08%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles	$3.631K	$3.772K	$3.913K
YoY Change
Long-Term Investments	$1.122M	$1.344M	$1.534M
YoY Change	-35.08%
Other Assets
YoY Change
Total Long-Term Assets	$1.125M	$1.348M	$1.538M
YoY Change	-35.03%	43.85%	61.4%
TOTAL ASSETS
Total Short-Term Assets	$3.823M	$5.336M	$3.199M
Total Long-Term Assets	$1.125M	$1.348M	$1.538M
Total Assets	$4.949M	$6.684M	$4.737M
YoY Change	30.95%	71.32%	-17.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$316.7K	$177.5K	$127.4K
YoY Change	183.55%	-66.52%	-67.65%
Accrued Expenses	$335.2K	$375.3K	$525.7K
YoY Change	3.31%	-68.31%	-54.48%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$671.9K	$562.7K	$653.1K
YoY Change	45.51%	-68.7%	-63.53%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$671.9K	$562.7K	$653.1K
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$671.9K	$562.7K	$653.1K
YoY Change	45.51%	-77.14%	-73.41%
SHAREHOLDERS EQUITY
Retained Earnings	-$77.73M	-$75.27M	-$68.80M
YoY Change	18.69%	13.06%	8.05%
Common Stock	$4.292K	$4.054K	$1.663K
YoY Change	258.26%	-85.78%	-93.77%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$4.277M	$6.122M	$4.084M
YoY Change
Total Liabilities & Shareholders Equity	$4.949M	$6.684M	$4.737M
YoY Change	30.95%	71.32%	-17.38%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q4
OPERATING ACTIVITIES
Net Income	-$2.458M	-$6.477M	-$1.920M
YoY Change	-325.99%	122.88%	-33.01%
Depreciation, Depletion And Amortization	$140.00	$140.00	$560.00
YoY Change	-108.48%	-93.24%	-73.08%
Cash From Operating Activities	-$2.148M	-$1.626M	-$1.227M
YoY Change	13.39%	-29.26%	-29.93%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities			$350.0K
YoY Change
Cash From Investing Activities			$350.0K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	411.1K	$3.824M	3.382M
YoY Change	685066.67%	527.33%
NET CHANGE
Cash From Operating Activities	-2.148M	-$1.626M	-1.227M
Cash From Investing Activities			350.0K
Cash From Financing Activities	411.1K	$3.824M	3.382M
Net Change In Cash	-1.737M	$2.198M	2.505M
YoY Change	58.72%	-230.12%	-243.09%
FREE CASH FLOW
Cash From Operating Activities	-$2.148M	-$1.626M	-$1.227M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.19
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.75
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2953913	shares
CY2023Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2024Q1	dei	Entity Registrant Name EntityRegistrantName	ADIAL PHARMACEUTICALS, INC.
CY2024Q1	dei	Document Type DocumentType	10-Q
CY2024Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q1	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q1	dei	Entity File Number EntityFileNumber	001-38323
CY2024Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-3074668
CY2024Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	4870 Sadler Road
CY2024Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 300
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Glend Allen
CY2024Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	VA
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	23060
CY2024Q1	dei	City Area Code CityAreaCode	(804)
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	487-8196
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	4233308	shares
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5025110	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2827082	usd
CY2024Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	36000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	275356	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	371597	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	5336466	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	3198679	usd
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3772	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3913	usd
CY2024Q1	us-gaap	Equity Method Investments EquityMethodInvestments	1344143	usd
CY2023Q4	us-gaap	Equity Method Investments EquityMethodInvestments	1534013	usd
CY2024Q1	us-gaap	Assets Assets	6684381	usd
CY2023Q4	us-gaap	Assets Assets	4736605	usd
CY2024Q1	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	177468	usd
CY2023Q4	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	103325	usd
CY2023Q4	adil	Accounts Payable Related Party Currrent AccountsPayableRelatedPartyCurrrent	24062	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	375263	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	477747	usd
CY2024Q1	adil	Accrued Expenses Related Party Current AccruedExpensesRelatedPartyCurrent	10000	usd
CY2023Q4	adil	Accrued Expenses Related Party Current AccruedExpensesRelatedPartyCurrent	47942	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	562731	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	653076	usd
CY2024Q1	us-gaap	Liabilities Liabilities	562731	usd
CY2023Q4	us-gaap	Liabilities Liabilities	653076	usd
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4054861	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4054861	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1663421	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1663421	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	4054	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	1663	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	81392028	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	72879738	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-75274432	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-68797872	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	6121650	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	4083529	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6684381	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4736605	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	454278	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	365616	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1390744	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1903159	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	1845022	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	2268775	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1845022	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2268775	usd
CY2024Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	22801	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	28892	usd
CY2024Q1	adil	Inducement Expenses InducementExpenses	-4464427	usd
CY2024Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-189870	usd
CY2024Q1	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	42	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4631538	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	28892	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6476560	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2239883	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-6476560	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-2239883	usd
CY2023Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-665953	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-6476560	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2905836	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-2.19
CY2023Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-2.12
CY2023Q1	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare	-0.63
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.19
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.75
CY2024Q1	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	2953913	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	1058542	shares
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	4083529	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	177003	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	48987	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3824264	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4464427	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-6476560	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	6121650	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	3276494	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	397442	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	62135	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	609613	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2905836	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	1439848	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-6476560	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-2239883	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	225990	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	459577	usd
CY2024Q1	adil	Warrant Exercise Inducement Expense WarrantExerciseInducementExpense	4464427	usd
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	141	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	141	usd
CY2024Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-189870	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-96241	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-126085	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	36000	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-102484	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	183721	usd
CY2024Q1	adil	Increase Decrease In Accrued Expenses Related Party IncreaseDecreaseInAccruedExpensesRelatedParty	-37942	usd
CY2023Q1	adil	Increase Decrease In Accrued Expenses Related Party IncreaseDecreaseInAccruedExpensesRelatedParty	-153980	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	74143	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	86367	usd
CY2024Q1	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-24062	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-1626236	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-1537972	usd
CY2023Q1	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-760841	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1626236	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2298813	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	609613	usd
CY2024Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	3824264	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3824264	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	609613	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	2198028	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-1689200	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2827082	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4001794	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5025110	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2312594	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	3800000	usd
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Use of Estimates</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of these unaudited condensed consolidated financial statements in conformity with GAAP requires Company management to make estimates and assumptions the affect the amounts of assets and liabilities at the date of these consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results might differ from these estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Significant items subject to such estimates and assumptions include accruals associated with third party providers supporting clinical trials and income tax asset realization.</p>
CY2024Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	4201568	shares
CY2023Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	491151	shares
CY2024Q1	us-gaap	Incremental Common Shares Attributable To Contingently Issuable Shares IncrementalCommonSharesAttributableToContingentlyIssuableShares	357194	shares
CY2023Q1	us-gaap	Incremental Common Shares Attributable To Contingently Issuable Shares IncrementalCommonSharesAttributableToContingentlyIssuableShares	172679	shares
CY2024Q1	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	23330	shares
CY2023Q1	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	36666	shares
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4582092	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	700496	shares
CY2024Q1	us-gaap	Cash Uninsured Amount CashUninsuredAmount	2700000	usd
CY2023Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	927000	usd
CY2023Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	1600000	usd
CY2024Q1	us-gaap	Business Combination Provisional Information Initial Accounting Incomplete Adjustment Equity Interests BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentEquityInterests	1727897	usd
CY2023Q3	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	189870	usd
CY2024Q1	adil	Clinical Research Organization Services And Clinical Consulting Services ClinicalResearchOrganizationServicesAndClinicalConsultingServices	96662	usd
CY2024Q1	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	196118	usd
CY2023Q4	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	421365	usd
CY2024Q1	adil	Preclinical And Manufacturing Expenses PreclinicalAndManufacturingExpenses	76667	usd
CY2023Q4	adil	Preclinical And Manufacturing Expenses PreclinicalAndManufacturingExpenses	50566	usd
CY2024Q1	adil	Legal And Consulting Services LegalAndConsultingServices	5816	usd
CY2023Q4	adil	Legal And Consulting Services LegalAndConsultingServices	5816	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	375263	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	477747	usd
CY2024Q1	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	3529	usd
CY2023Q1	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	0	usd
CY2023Q2	us-gaap	Line Of Credit Facility Commitment Fee Amount LineOfCreditFacilityCommitmentFeeAmount	3000000	usd
CY2023Q2	us-gaap	Additional Collateral Aggregate Fair Value AdditionalCollateralAggregateFairValue	500000	usd
CY2023Q2	adil	Daily Trading Value DailyTradingValue	2000000	usd
CY2023Q2	adil	Weighted Average Price Percentage WeightedAveragePricePercentage	0.95	pure
CY2024Q1	us-gaap	Other Expenses OtherExpenses	51901	usd
CY2024Q1	us-gaap	Debt Conversion Converted Instrument Warrants Or Options Issued1 DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1	1150000	shares
CY2024Q1	adil	Aggregate Purchase Price AggregatePurchasePrice	2.82	usd
CY2024Q1	us-gaap	Sale Leaseback Transaction Gross Proceeds Investing Activities SaleLeasebackTransactionGrossProceedsInvestingActivities	3500000	usd
CY2024Q1	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	3100000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.066
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue	1.94
CY2024Q1	us-gaap	Deferred Sales Inducements Amortization Expense DeferredSalesInducementsAmortizationExpense	4464427	usd
CY2023Q3	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	500000	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	1.35
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y9M
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.1189	pure
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0423	pure
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	232812	usd
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	1.14
CY2024Q1	us-gaap	Unrecognized Tax Benefits Income Tax Penalties Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense	746346	usd
CY2024Q1	adil	Weighted Average Remaining Service Period WeightedAverageRemainingServicePeriod	P1Y9M10D
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	225990	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	459577	usd
CY2023	adil	Warrants Outstanding WarrantsOutstanding	973000	shares
CY2024Q1	adil	License Fees And Milestone Payments Description LicenseFeesAndMilestonePaymentsDescription	More specifically, the Company paid UVA LVG a license issue fee and is obligated to pay UVA LVG (i) annual minimum royalties of $40,000 commencing in 2017; (ii) a $20,000 milestone payments upon dosing the first patient under a Phase 3 human clinical trial of a licensed product, $155,000 upon the earlier of the completion of a Phase 3 trial of a licensed product, partnering of a licensed product, or sale of the Company, $275,000 upon acceptance of an NDA by the FDA, and $1,000,000 upon approval for sale of AD04 in the U.S., Europe or Japan; as well as (iii) royalties equal to a 2% and 1% of net sales of licensed products in countries in which a valid patent exists or does not exist, respectively, with royalties paid quarterly. In the event of a sublicense to a third party, the Company is obligated to pay royalties to UVA LVG equal to a percentage of what the Company would have been required to pay to UVA LVG had it sold the products under sublicense ourselves. In addition, the Company is required to pay to UVA LVG 15% of any sublicensing income.
CY2024Q1	us-gaap	Royalty Expense RoyaltyExpense	10000	usd
CY2023Q1	us-gaap	Royalty Expense RoyaltyExpense	10000	usd
CY2018Q2	us-gaap	Deferred Compensation Arrangement With Individual Cash Awards Granted Percentage DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage	0.05	pure
CY2018Q2	us-gaap	Grants Receivable GrantsReceivable	1000000	usd
CY2018Q2	us-gaap	Investment Interest Rate Paid In Cash InvestmentInterestRatePaidInCash	0.50	pure
CY2018Q2	us-gaap	Preferred Stock Dividend Rate Percentage PreferredStockDividendRatePercentage	0.50	pure
CY2024Q1	adil	Annual Fee AnnualFee	375000	usd
CY2022Q3	adil	Annual Fee AnnualFee	430000	usd
CY2022Q4	us-gaap	Other Commitment OtherCommitment	209250	usd
CY2023Q1	us-gaap	Deferred Compensation Arrangement With Individual Distribution Paid DeferredCompensationArrangementWithIndividualDistributionPaid	22000	usd
CY2024Q1	us-gaap	Payment For Administrative Fees PaymentForAdministrativeFees	25000	usd
CY2024Q1	us-gaap	Other General Expense OtherGeneralExpense	73620	usd
CY2023Q1	us-gaap	Other General Expense OtherGeneralExpense	18333	usd
CY2024Q1	adil	Future Cash FutureCash	150000	usd
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	adil	Accounts Payable Related Party Currrent AccountsPayableRelatedPartyCurrrent		usd
CY2023Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments		usd
CY2023Q1	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense		usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2024Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax		usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-2.12
CY2024Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-2.19
CY2024Q1	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
CY2023Q1	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare	-0.63
CY2024Q1	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1058542	shares
CY2023Q1	adil	Warrant Exercise Inducement Expense WarrantExerciseInducementExpense		usd
CY2023Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments		usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther		usd
CY2023Q1	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities		usd
CY2024Q1	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations		usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2023Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2024Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2023Q4	adil	Clinical Research Organization Services And Clinical Consulting Services ClinicalResearchOrganizationServicesAndClinicalConsultingServices		usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments		usd
CY2024Q1	dei	Amendment Flag AmendmentFlag	false
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001513525

Files In Submission

Name	View Source	Status
0001213900-24-043023-index-headers.html	Edgar Link	pending
0001213900-24-043023-index.html	Edgar Link	pending
0001213900-24-043023.txt	Edgar Link	pending
0001213900-24-043023-xbrl.zip	Edgar Link	pending
adil-20240331.xsd	Edgar Link	pending
ea0205885-10q_adialpharma.htm	Edgar Link	pending
ea0205885ex31-1_adialpharma.htm	Edgar Link	pending
ea0205885ex31-2_adialpharma.htm	Edgar Link	pending
ea0205885ex32-1_adialpharma.htm	Edgar Link	pending
ea0205885ex32-2_adialpharma.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
adil-20240331_def.xml	Edgar Link	unprocessable
adil-20240331_lab.xml	Edgar Link	unprocessable
adil-20240331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
ea0205885-10q_adialpharma_htm.xml	Edgar Link	completed
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
adil-20240331_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ADIL
ADIAL PHARMACEUTICALS, INC. Stock $adil

2024 Q2 Form 10-Q Financial Statement

#000121390024043023 Filed on May 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ADIL ADIAL PHARMACEUTICALS, INC. Stock $adil

2024 Q2 Form 10-Q Financial Statement

#000121390024043023 Filed on May 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ADIL
ADIAL PHARMACEUTICALS, INC. Stock $adil